Cognitive Assessment Tools for Huntington's Disease.

Launched by OHIO STATE UNIVERSITY · Aug 6, 2024

Keywords

ClinConnect Summary

This clinical trial is studying two cognitive assessment tools, the Coding Test and the Self-Administered Gerocognitive Examination (SAGE), to see how they can help people with Huntington's Disease (HD). These tests are already used for other brain diseases, like Alzheimer’s and Parkinson’s, but researchers want to find out how effective they are for people with HD. The goal is to improve the way we screen for cognitive issues and how we conduct clinical trials for this condition.

To participate in the trial, individuals need to be between 30 and 65 years old and have a genetic diagnosis of Huntington's Disease. They should also have clear vision and hearing to complete the tests and have been on stable medications for at least 30 days before signing up. It’s important to note that certain serious health conditions or a history of learning disabilities may exclude someone from participating. If eligible, participants can expect to undergo these cognitive assessments, which may help advance understanding of Huntington's Disease and improve future treatments.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Males and females aged 30-65 (inclusive) at the time of signing the informed consent form.
• • 2. Genetic diagnosis of HD as defined by a CAG repeat size ≥ 40.
• • 3. A clinical diagnosis of HD as defined by a Diagnostic Confidence Level (DCL) of 4.
• • 4. Vision and hearing sufficient for compliance with tests.
• • 5. On a stable dose of medications for 30 days prior to the time of signing the informed consent form.
• Exclusion Criteria:
• • 1. Age of symptom onset less than 19 years old or greater than 60 years old.
• • 2. Any serious neurological disorder aside from HD, including but not limited to Alzheimer's disease, Parkinson's disease, Frontotemporal dementia, Lewy body dementia, Amyotrophic Lateral Sclerosis, Traumatic Brain Injury... etc. that in the opinion of the investigator is clinically significant.
• • 3. Any ongoing serious medical condition that in the opinion of the investigator is clinically significant. This includes autoimmune diseases, ongoing treatment for cancer, congestive heart failure, severe pulmonary disease, or any history of a seizure disorder (including the need to take anti-epileptics to prevent seizure).
• • 4. Subjects who are pregnant or breast feeding
• • 5. Subjects with a history of a learning disability.
• • 6. Subjects who are unable to provide consent.